Ernst and Young Technical Line: Implementing the medical device excise tax Continue reading
Category Archives: Advocacy and Regulations
Leaders in the Innovation Economy Reach out to Senate Leadership on Medical Device Tax Repeal
Leaders from over 800 organiztions and companies focused on grwoing our econony and supporting medical device innovation sent a letter to Senate leadership this today calling for repeal of the medical device tax.
The letter included three important reasons to suport repeal:
-
The tax will stifle innovation and cost thousands of high-paying jobs. It will increase the effective tax rate for many medical technology companies, thereby reducing financial resources that should be used for R&D, clinical trials and investments in manufacturing. The impact will be especially hard on smaller companies whose innovations are not immediately profitable.
-
The tax will increase health care costs as confirmed by a report issued in April 2010 by the Office of the Actuary at the Centers for Medicare and Medicaid Services (CMS). In some cases, the 2.3% tax will be passed on to consumers, leading to higher health care costs.
-
The tax will not be offset by increased demand for medical devices. In fact, it is important to note that there is no evidence suggesting a device industry “windfall” from healthcare reform. Unlike other industries that may benefit from expanded coverage, the majority of device-intensive medical procedures are performed on patients that are older and already have private insurance or Medicare coverage. Where states have dramatically extended health coverage, such as in Massachusetts where they added 400,000 new covered lives, there is no evidence of a device “windfall.”
At a time when the federal government is working to promote investment in U.S. industries of the future, it is inconsistent that a tax of this magnitude would be considered on the medical device industry. We must do all we can to encourage and promote research, development, investment and innovation. Instead, increased taxes, such as this one on the medical device industry, coupled with the increased regulatory uncertainty the industry also faces, will lead to further job losses, hinder the development of breakthrough treatments and delay patient access to medical technology.
To read the full text and view the list of signatories, please cliche here: 2012-11-13 Medical Device Tax letter to Senate Leadership
AZBio Honors Arizona Legislative Leaders As Trailblazers
AZBio honors Arizona Legislators with 2012 Trailblazer Award:
Carter, Campbell, McCune Davis, McComish, Melvin, Taylor Landrum, Tobin, Tovar, Williams, and Yee recognized for supporting research, education, innovation and the growth of Arizona’s bioscience sector.Continue reading
Regenesis CEO Virginia Rybski Chats with Beaker.com
Regenesis Biomedical’s CEO, Virginia Rybski, chats with the team at Beaker.com on her expereince at AdvaMed 2011 as well as shares a story of growth and progress.Continue reading
Member Spotlight: JE Hamilton and Associates
With a focus on helping pharmaceutical, biotechnology and other life science companies meet their quality and compliance goals, JE Hamilton & Associates is relocating to the AZ Techcelerator, a business incubator designed to promote and encourage promising new business endeavors.Continue reading
Making a Difference: AZBio Advocacy in Support of BioFuels Initiatives
When AZBio and AZBio Members work together with our partners across the country, we can make a difference. AZBio member Robert Shatz of Arizona CarbonTech Cooperative, Inc. shares a real-world example of advocacy and partnership in action.Continue reading
FDA Publishes Prescription Drug User Fee Rates for Fiscal Year 2013
A Notice by the Food and Drug Administration on 08/01/2012 via The Federal RegisterContinue reading
Get the G2 on changes on the SBIR/STTR Program from the source
SBIR and STTR Policy Directives Are Finalized but Await Public Comment for ImprovementsContinue reading
Got Grants? Important Update: CCR is out SAM is In
The Central Contractor Registry (CCR) as well as the Online Representations and Certifications Application (ORCA) web sites and facilities have given way to the federal government’s new omnibus system, the System for Award Management (SAM).Continue reading